HIV-2感染者一线联合抗逆转录病毒治疗后CD4细胞恢复较HIV-1感染者差:欧洲多队列研究
该多队列研究比较了HIV-2与HIV-1感染者一线cART后CD4细胞恢复情况,纳入185例HIV-2和30321例HIV-1初治成人。调整基线病毒载量等混杂因素后,HIV-2感染者CD4细胞年均增幅较HIV-1低25 cells/mm3(95%CI 5-44;P=0.0127),提示需针对HIV-2探索更强效方案。
要点
- HIV-2感染者一线cART后CD4恢复显著差于HIV-1感染者。
- 调整基线病毒载量等后,CD4年增幅仍低25 cells/mm3(95%CI 5-44)。
- 需为HIV-2感染者寻找更强效的治疗方案或策略。
核心结论
- HIV-2感染者一线cART后CD4细胞增加较HIV-1感染者更差,即使调整基线血浆病毒载量和其他潜在混杂因素后仍存在差异。
研究设计与样本
- 研究纳入COHERE(仅HIV-1)和ACHIeV2e(仅HIV-2)两个欧洲多队列合作中1997至2011年间启动一线cART(不含NNRTI或融合抑制剂)的初治HIV成人。
- 最终纳入185例HIV-2感染者和30321例HIV-1感染者,采用调整线性混合模型分析CD4细胞计数演变。
主要发现
- HIV-2感染者中位年龄46岁(IQR 36-52),HIV-1感染者37岁(IQR 31-44)。
- HIV-2感染者基线中位CD4计数为203 cells/mm3(95%CI 100-290),HIV-1感染者为223 cells/mm3(95%CI 100-353)。
- cART启动至12个月时,HIV-2感染者CD4平均观察变化为+105 cells/mm3(95%CI 77-134),HIV-1感染者为+202 cells/mm3(95%CI 199-205),观察差异为1年97 cells/mm3。
- 调整分析中,HIV-2感染者CD4细胞平均年增加较HIV-1感染者低25 cells/mm3(95%CI 5-44;P=0.0127)。
临床怎么用
- 临床应认识到HIV-2感染者一线cART后CD4恢复可能不如HIV-1感染者,需密切监测免疫重建。
- 对HIV-2感染者应考虑探索或选用更强效的治疗方案或策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: CD4 cell recovery following first-line combination ART (cART) is poorer in HIV-2+ than in HIV-1+ patients. Only large comparisons may allow adjustments for demographic and pretreatment plasma viral load (pVL). METHODS: ART-naive HIV+ adults from two European multicohort collaborations, COHERE (HIV-1 alone) and ACHIeV2e (HIV-2 alone), were included, if they started first-line cART (without NNRTIs or fusion inhibitors) between 1997 and 2011. Patients without at least one CD4 cell count before start of cART, without a pretreatment pVL and with missing a priori-defined covariables were excluded. Evolution of CD4 cell count was studied using adjusted linear mixed models. RESULTS: We included 185 HIV-2+ and 30321 HIV-1+ patients with median age of 46 years (IQR 36-52) and 37 years (IQR 31-44), respectively. Median observed pretreatment CD4 cell counts/mm3 were 203 (95% CI 100-290) in HIV-2+ patients and 223 (95% CI 100-353) in HIV-1+ patients. Mean observed CD4 cell count changes from start of cART to 12 months were +105 (95% CI 77-134) in HIV-2+ patients and +202 (95% CI 199-205) in HIV-1+ patients, an observed difference of 97 cells/mm3 in 1 year. In adjusted analysis, the mean CD4 cell increase was overall 25 CD4 cells/mm3/year lower (95% CI 5-44; P = 0.0127) in HIV-2+ patients compared with HIV-1+ patients. CONCLUSIONS: A poorer CD4 cell increase during first-line cART was observed in HIV-2+ patients, even after adjusting for pretreatment pVL and other potential confounders. Our results underline the need to identify more potent therapeutic regimens or strategies against HIV-2.
引用
- Wittkop L, Arsandaux J, Trevino A, et al. CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study. J Antimicrob Chemother. 2017. PMID: 29091198. doi:10.1093/jac/dkx210
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。